Kopran Ltd
NSE:KOPRAN

Watchlist Manager
Kopran Ltd Logo
Kopran Ltd
NSE:KOPRAN
Watchlist
Price: 129.65 INR -0.54% Market Closed
Market Cap: 6.3B INR

Relative Value

The Relative Value of one KOPRAN stock under the Base Case scenario is 204.14 INR. Compared to the current market price of 129.65 INR, Kopran Ltd is Undervalued by 36%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

KOPRAN Relative Value
Base Case
204.14 INR
Undervaluation 36%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
93
vs Industry
63
Median 3Y
1.6
Median 5Y
1.7
Industry
2.6
vs History
11
vs Industry
25
Median 3Y
24.7
Median 5Y
21.3
Industry
21.6
vs History
79
vs Industry
15
Median 3Y
21.5
Median 5Y
18.3
Industry
16.5
vs History
60
vs Industry
0
Median 3Y
18.5
Median 5Y
31.9
Industry
22.5
vs History
96
vs Industry
41
Median 3Y
2
Median 5Y
2.3
Industry
2.3
vs History
87
vs Industry
62
Median 3Y
1.7
Median 5Y
1.7
Industry
2.9
vs History
82
vs Industry
48
Median 3Y
5.1
Median 5Y
5.1
Industry
5.5
vs History
47
vs Industry
28
Median 3Y
14.5
Median 5Y
14
Industry
13
vs History
25
vs Industry
27
Median 3Y
18.4
Median 5Y
17.6
Industry
16.6
vs History
77
vs Industry
15
Median 3Y
23.8
Median 5Y
19.1
Industry
15.8
vs History
14
vs Industry
3
Median 3Y
-35.6
Median 5Y
-17.8
Industry
19.1
vs History
98
vs Industry
45
Median 3Y
1.6
Median 5Y
1.9
Industry
1.9

Multiples Across Competitors

KOPRAN Competitors Multiples
Kopran Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Kopran Ltd
NSE:KOPRAN
6.3B INR 1.1 35.6 14.1 20.1
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.8 54.3 36.5 39.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
504B USD 5.5 20.1 16.4 21.3
CH
Roche Holding AG
SIX:ROG
252.4B CHF 4.1 26.8 11.5 13.4
UK
AstraZeneca PLC
LSE:AZN
210.7B GBP 4.9 30.1 108.7 159.1
CH
Novartis AG
SIX:NOVN
206.8B CHF 4.6 18.1 11.5 14.8
US
Merck & Co Inc
NYSE:MRK
245.9B USD 3.8 12.9 9.2 10.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.3 13.1 9.2 10.7
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
143B USD 2.3 14.6 7.4 10.1
P/E Multiple
Earnings Growth PEG
IN
Kopran Ltd
NSE:KOPRAN
Average P/E: 25.1
35.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.3
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.1
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.8
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30.1
38%
0.8
CH
Novartis AG
SIX:NOVN
18.1
17%
1.1
US
Merck & Co Inc
NYSE:MRK
12.9
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.1
4%
3.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Kopran Ltd
NSE:KOPRAN
Average EV/EBITDA: 400.2
14.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.5
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.4
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.5
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.7
10%
10.9
CH
Novartis AG
SIX:NOVN
11.5
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.2
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.2
2%
4.6
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Kopran Ltd
NSE:KOPRAN
Average EV/EBIT: 1 712
20.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.1
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.3
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.4
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
159.1
23%
6.9
CH
Novartis AG
SIX:NOVN
14.8
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.9
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.7
1%
10.7
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
8%
1.3